Peptide TFP5/TP5 derived from Cdk5 activator P35 provides neuroprotection in the MPTP model of Parkinson's disease

Molecular Biology of the Cell

Volumn 26, Issue 24, 2015, Pages 4478-4491

  Binukumar, B K ^a   Shukla, Varsha ^a   Amin, Niranjana D ^a   Grant, Philip ^a   Bhaskar, M ^a   Skuntz, Susan ^a   Steiner, Joseph ^a   Pant, Harish C ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CYCLIN DEPENDENT KINASE 5; PROTEIN P25; PROTEIN P35; TFP5 PEPTIDE; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE; NERVE PROTEIN; NEURONAL CDK5 ACTIVATOR (P25-P35); NEUROPROTECTIVE AGENT; PEPTIDE FRAGMENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOSOLIC FRACTION; DNA FRAGMENTATION; DOPAMINERGIC NERVE CELL; IMMUNOPRECIPITATION; IMMUNOREACTIVITY; LOCOMOTION; MESENCEPHALIC TISSUE; MICROGLIA; MOUSE; NERVE CELL CULTURE; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIMARY CULTURE; PRIORITY JOURNAL; WESTERN BLOTTING; AMINO ACID SEQUENCE; ANIMAL; C57BL MOUSE; CHEMISTRY; DISEASE MODEL; MALE; METABOLISM; MOLECULAR GENETICS; NERVE CELL; SUBSTANTIA NIGRA;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; AMINO ACID SEQUENCE; ANIMALS; CYCLIN-DEPENDENT KINASE 5; DISEASE MODELS, ANIMAL; DOPAMINE; MALE; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; NERVE TISSUE PROTEINS; NEURONS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; PEPTIDE FRAGMENTS; SUBSTANTIA NIGRA;

EID: 84949058159     PISSN: 10591524     EISSN: 19394586     Source Type: Journal    
DOI: 10.1091/mbc.E15-06-0415     Document Type: Article

References (67)

1. Ahlijanian MK, Barrezueta NX, Williams RD, Jakowski A, Kowsz K P, McCarthy S, Coskran T, Carlo A, Seymour PA, Burkhardt JE, et al. (2000). Hyperphosphorylated tau and neuroflament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5. Proc Natl Acad Sci USA 97, 2910-2915.
2. Amin ND, Albers W, Pant HC (2002). Cyclin-dependent kinase 5 (cdk5) activation requires interaction with three domains of p35. J Neurosci Res 67, 354-362.
3. Bifsha P, Yang J, Fisher RA, Drouin J (2014). Rgs6 is required for adult maintenance of dopaminergic neurons in the ventral substantia nigra. PLoS Genet 10, e1004863.
4. Binukumar BK, Zheng YL, Shukla V, Amin ND, Grant P, Pant HC (2014). TFP5, a peptide derived from p35, a Cdk5 neuronal activator, rescues cortical neurons from glucose toxicity. J Alzheimers Dis 39, 899-909.
5. Block ML, Zecca L, Hong JS (2007). Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 8, 57-69.
6. Brion J P, Couck AM (1995). Cortical and brainstem-type Lewy bodies are immunoreactive for the cyclin-dependent kinase 5. Am J Pathol 147, 1465-1476.
7. Chen TS, Koutsilieri E, Rausch WD (1995). MPP+ selectively affects calcium homeostasis in mesencephalic cell cultures from embryonal C57/Bl6 mice. J Neural Transm Gen Sect 100, 153-163.
8. Cheung ZH, Ip NY (2004). Cdk5: mediator of neuronal death and survival. Neurosci Lett 361, 47-51.
9. Chung YC, Bok E, Huh SH, Park JY, Yoon SH, Kim SR, Kim YS, Maeng S, Park SH, Jin BK (2011). Cannabinoid receptor type 1 protects nigros-triatal dopaminergic neurons against MPTP neurotoxicity by inhibiting microglial activation. J Immunol 187, 6508-6517.
10. Chung YC, Kim SR, Jin BK (2010). Paroxetine prevents loss of nigrostriatal dopaminergic neurons by inhibiting brain infammation and oxidative stress in an experimental model of Parkinson's disease. J Immunol 185, 1230-1237.
11. Crews L, Patrick C, Adame A, Rockenstein E, Masliah E (2011). Modulation of aberrant CDK5 signaling rescues impaired neurogenesis in models of Alzheimer's disease. Cell Death Dis 2, e120.
12. Croisier E, Moran LB, Dexter DT, Pearce RK, Graeber MB (2005). Microglial infammation in the parkinsonian substantia nigra: relationship to alpha-synuclein deposition. J Neuroinfammation 2, 14.
13. Cruz JC, Tseng HC, Goldman JA, Shih H, Tsai LH (2003). Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegen-eration and neurofbrillary tangles. Neuron 40, 471-483.
14. Du Y, Ma Z, Lin S, Dodel RC, Gao F, Bales KR, Triarhou LC, Chernet E, Perry KW, Nelson DL, et al. (2001). Minocycline prevents nigrostriatal dopa-minergic neurodegeneration in the MPTP model of Parkinson's disease. Proc Natl Acad Sci USA 98, 14669-14674.
15. Franco-Iborra S, Vila M, Perier C (2015). The Parkinson disease mitochondrial hypothesis: where are we at? Neuroscientist, 1073858415574600.
16. Fredriksson A, Palomo T, Archer T (1999). Effects of co-administration of an-ticonvulsant and putative anticonvulsive agents and sub/suprathreshold doses of L-dopa upon motor behaviour of MPTP-treated mice. J Neural Transm 106, 889-909.
17. Gao HM, Jiang J, Wilson B, Zhang W, Hong JS, Liu B (2002). Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease. J Neurochem 81, 1285-1297.
18. Gentil B, Grimot F, Riva C (2003). Commitment to apoptosis by ceramides depends on mitochondrial respiratory function, cytochrome c release and caspase-3 activation in Hep-G2 cells. Mol Cell Biochem 254, 203-210.
19. Ghosh A, Saminathan H, Kanthasamy A, Anantharam V, Jin H, Sondarva G, Harischandra DS, Qian Z, Rana A, Kanthasamy AG (2013). The peptidyl-prolyl isomerase Pin1 up-regulation and proapoptotic function in dopa-minergic neurons: relevance to the pathogenesis of Parkinson disease. J Biol Chem 288, 21955-21971.
20. Gong X, Tang X, Wiedmann M, Wang X, Peng J, Zheng D, Blair LA, Marshall J, Mao Z (2003). Cdk5-mediated inhibition of the protective effects of transcription factor MEF2 in neurotoxicity-induced apoptosis. Neuron 38, 33-46.
21. Helal CJ, Kang Z, Lucas JC, Gant T, Ahlijanian MK, Schachter JB, Richter KE, Cook JM, Menniti FS, Kelly K, et al. (2009). Potent and cellularly active 4-aminoimidazole inhibitors of cyclin-dependent kinase 5/p25 for the treatment of Alzheimer's disease. Bioorg Med Chem Lett 19, 5703-5707.
22. Helal CJ, Sanner MA, Cooper CB, Gant T, Adam M, Lucas JC, Kang Z, Kupchinsky S, Ahlijanian MK, Tate B, et al. (2004). Discovery and SAR of 2-aminothiazole inhibitors of cyclin-dependent kinase 5/p25 as a potential treatment for Alzheimer's disease. Bioorg Med Chem Lett 14, 5521-5525.
23. Huang E, Qu D, Zhang Y, Venderova K, Haque ME, Rousseaux MW, Slack RS, Woulfe JM, Park DS (2010). The role of Cdk5-mediated apurinic/apyrimidinic endonuclease 1 phosphorylation in neuronal death. Nat Cell Biol 12, 563-571.
24. Jackson-Lewis V, Przedborski S (2007). Protocol for the MPTP mouse model of Parkinson's disease. Nat Protoc 2, 141-151.
25. Klevenyi P, Andreassen O, Ferrante RJ, Schleicher JR Jr., Friedlander RM, Beal MF (1999). Transgenic mice expressing a dominant negative mutant interleukin-1beta converting enzyme show resistance to MPTP neurotoxicity. Neuroreport 10, 635-638.
26. Lau LF, Ahlijanian MK (2003). Role of cdk5 in the pathogenesis of Alzheimer's disease. Neurosignals 12, 209-214.
27. Lee MS, Kwon YT, Li M, Peng J, Friedlander RM, Tsai LH (2000). Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature 405, 360-364.
28. Levy OA, Malagelada C, Greene LA (2009). Cell death pathways in Parkinson's disease: proximal triggers, distal effectors, and fnal steps. Apoptosis 14, 478-500.
29. Li H, Zhu H, Xu CJ, Yuan J (1998). Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94, 491-501.
30. Liberatore GT, Jackson-Lewis V, Vukosavic S, Mandir AS, Vila M, McAuliffe WG, Dawson VL, Dawson TM, Przedborski S (1999). Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat Med 5, 1403-1409.
31. Lim AC, Qu D, Qi RZ (2003). Protein-protein interactions in Cdk5 regulation and function. Neurosignals 12, 230-238.
32. Liu WB, Zhou J, Qu Y, Li X, Lu CT, Xie KL, Sun XL, Fei Z (2010). Neuropro-tective effect of osthole on MPP+-induced cytotoxicity in PC12 cells via inhibition of mitochondrial dysfunction and ROS production. Neuro-chem Int 57, 206-215.
33. McGeer PL, McGeer EG (2004). Infammation and neurodegeneration in Parkinson's disease. Parkinsonism Relat Disord 10(Suppl 1), S3-S7.
34. Meuer K, Suppanz IE, Lingor P, Planchamp V, Goricke B, Fichtner L, Braus GH, Dietz G P, Jakobs S, Bahr M, Weishaupt JH (2007). Cyclin-depen-dent kinase 5 is an upstream regulator of mitochondrial fssion during neuronal apoptosis. Cell Death Differ 14, 651-661.
35. Mizuno Y, Yoshino H, Ikebe S, Hattori N, Kobayashi T, Shimoda-Matsu-bayashi S, Matsumine H, Kondo T (1998). Mitochondrial dysfunction in Parkinson's disease. Ann Neurol 44, S99-109.
36. Nagatsu T, Mogi M, Ichinose H, Togari A (2000). Changes in cytokines and neurotrophins in Parkinson's disease. J Neural Transm Suppl 2000, 277-290.
37. Nakamura S, Kawamoto Y, Nakano S, Akiguchi I, Kimura J (1997). p35nck5a and cyclin-dependent kinase 5 colocalize in Lewy bodies of brains with Parkinson's disease. Acta Neuropathol 94, 153-157.
38. Nguyen MD, Julien JP (2003). Cyclin-dependent kinase 5 in amyotrophic lateral sclerosis. Neurosignals 12, 215-220.
39. Nguyen MD, Lariviere RC, Julien JP (2001). Deregulation of Cdk5 in a mouse model of ALS: toxicity alleviated by perikaryal neuroflament inclusions. Neuron 30, 135-147.
40. Nguyen KC, Rosales JL, Barboza M, Lee KY (2002). Controversies over p25 in Alzheimer's disease. J Alzheimers Dis 4, 123-126.
41. Noble W, Olm V, Takata K, Casey E, Mary O, Meyerson J, Gaynor K, LaFrancois J, Wang L, Kondo T, et al. (2003). Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron 38, 555-565.
42. Ossola B, Schendzielorz N, Chen SH, Bird GS, Tuominen RK, Mannisto PT, Hong JS (2011). Amantadine protects dopamine neurons by a dual action: reducing activation of microglia and inducing expression of GDNF in astroglia [corrected]. Neuropharmacology 61, 574-582.
43. Patrick GN, Zukerberg L, Nikolic M, de la Monte S, Dikkes P, Tsai LH (1999). Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 402, 615-622.
44. Przedborski S, Jackson-Lewis V (1998). Mechanisms of MPTP toxicity. Mov Disord 13(Suppl 1), 35-38.
45. Qu D, Rashidian J, Mount MP, Aleyasin H, Parsanejad M, Lira A, Haque E, Zhang Y, Callaghan S, Daigle M, et al. (2007). Role of Cdk5-mediated phosphorylation of Prx2 in MPTP toxicity and Parkinson's disease. Neuron 55, 37-52.
46. Savitt JM, Dawson VL, Dawson TM (2006). Diagnosis and treatment of Parkinson disease: molecules to medicine. J Clin Invest 116, 1744-1754.
47. Schapira AH, Gu M, Taanman JW, Tabrizi SJ, Seaton T, Cleeter M, Cooper JM (1998). Mitochondria in the etiology and pathogenesis of Parkinson's disease. Ann Neurol 44, S89-S98.
48. Shukla V, Zheng YL, Mishra SK, Amin ND, Steiner J, Grant P, Kesavapany S, Pant HC (2013). A truncated peptide from p35, a Cdk5 activator, prevents Alzheimer's disease phenotypes in model mice. FASEB J 27, 174-186.
49. Slevin M, Krupinski J (2009). Cyclin-dependent kinase-5 targeting for isch-aemic stroke. Curr Opin Pharmacol 9, 119-124.
50. Smith PD, Crocker SJ, Jackson-Lewis V, Jordan-Sciutto KL, Hayley S, Mount M P, O'Hare MJ, Callaghan S, Slack RS, Przedborski S, et al. (2003). Cyclin-dependent kinase 5 is a mediator of dopaminergic neuron loss in a mouse model of Parkinson's disease. Proc Natl Acad Sci USA 100, 13650-13655.
51. Smith PD, Mount M P, Shree R, Callaghan S, Slack RS, Anisman H, Vincent I, Wang X, Mao Z, Park DS (2006). Calpain-regulated p35/cdk5 plays a central role in dopaminergic neuron death through modulation of the transcription factor myocyte enhancer factor 2. J Neurosci 26, 440-447.
52. Sriram K, Matheson JM, Benkovic SA, Miller DB, Luster MI, O'Callaghan JP (2002). Mice defcient in TNF receptors are protected against dopami-nergic neurotoxicity: implications for Parkinson's disease. FASEB J 16, 1474-1476.
53. Stennicke HR, Salvesen GS (2000). Caspases-controlling intracellular signals by protease zymogen activation. Biochim Biophys Acta 1477, 299-306.
54. Sundaram JR, Poore C P, Sulaimee NH, Pareek T, Asad AB, Rajkumar R, Cheong W F, Wenk MR, Dawe GS, Chuang KH, et al. (2013). Specifc inhibition of p25/Cdk5 activity by the Cdk5 inhibitory peptide reduces neurodegeneration in vivo. J Neurosci 33, 334-343.
55. Teismann P, Tieu K, Cohen O, Choi DK, Wu DC, Marks D, Vila M, JacksonLewis V, Przedborski S (2003a). Pathogenic role of glial cells in Parkinson's disease. Mov Disord 18, 121-129.
56. Teismann P, Vila M, Choi DK, Tieu K, Wu DC, Jackson-Lewis V, Przedborski S (2003b). COX-2 and neurodegeneration in Parkinson's disease. Ann NY Acad Sci 991, 272-277.
57. Tsai LH, Lee MS, Cruz J (2004). Cdk5, a therapeutic target for Alzheimer's disease? Biochim Biophys Acta 1697, 137-142.
58. Venderova K, Park DS (2012). Programmed cell death in Parkinson's disease. Cold Spring Harb Perspect Med 2, a009365.
59. Vroon A, Drukarch B, Bol JG, Cras P, Breve JJ, Allan SM, Relton JK, Hoogland PV, Van Dam AM (2007). Neuroinfammation in Parkinson's patients and MPTP-treated mice is not restricted to the nigrostriatal system: microgliosis and differential expression of interleukin-1 receptors in the olfactory bulb. Exp Gerontol 42, 762-771.
60. Wen Z, Shu Y, Gao C, Wang X, Qi G, Zhang P, Li M, Shi J, Tian B (2014). CDK5-mediated phosphorylation and autophagy of RKIP regulate neuronal death in Parkinson's disease. Neurobiol Aging 35, 2870-2880.
61. Wu DC, Jackson-Lewis V, Vila M, Tieu K, Teismann P, Vadseth C, Choi DK, Ischiropoulos H, Przedborski S (2002). Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci 22, 1763-1771.
62. Wu DC, Teismann P, Tieu K, Vila M, Jackson-Lewis V, Ischiropoulos H, Przedborski S (2003). NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine model of Parkinson's disease. Proc Natl Acad Sci USA 100, 6145-6150.
63. Zhang L, Liu W, Szumlinski KK, Lew J (2012). p10, the N-terminal domain of p35, protects against CDK5/p25-induced neurotoxicity. Proc Natl Acad Sci USA 109, 20041-20046.
64. Zhao C, Ling Z, Newman MB, Bhatia A, Carvey PM (2007). TNF-alpha knockout and minocycline treatment attenuates blood-brain barrier leakage in MPTP-treated mice. Neurobiol Dis 26, 36-46.
65. Zheng YL, Amin ND, Hu YF, Rudrabhatla P, Shukla V, Kanungo J, Kesavapany S, Grant P, Albers W, Pant HC (2010). A 24-residue peptide (p5), derived from p35, the Cdk5 neuronal activator, specifcally inhibits Cdk5-p25 hyperactivity and tau hyperphosphorylation. J Biol Chem 285, 34202-34212.
66. Zheng YL, Kesavapany S, Gravell M, Hamilton RS, Schubert M, Amin N, Albers W, Grant P, Pant HC (2005). A Cdk5 inhibitory peptide reduces tau hyperphosphorylation and apoptosis in neurons. EMBO J 24, 209-220.
67. Zheng YL, Li BS, Amin ND, Albers W, Pant HC (2002). A peptide derived from cyclin-dependent kinase activator (p35) specifcally inhibits Cdk5 activity and phosphorylation of tau protein in transfected cells. Eur J Biochem 269, 4427-4434.